Quidel Q1 Revenues Drop 26 Percent | GenomeWeb

NEW YORK (GenomeWeb) — Quidel said after the close of the market Wednesday that first quarter revenues fell 26 percent to $46.7 million from $62.7 million in Q1 2013.

The decrease in revenue was due to lower sales of infectious disease products in Q1 2014, the result of a weak respiratory disease season.

In Q1, the company generated $18.3 million in total influenza product sales, as a year-over-year decrease in QuickVue Influenza product sales was partially offset by $6.2 million in Sofia Influenza revenue, a 42 percent increase over Q1 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.